Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Mouse Monoclonal [clone 3A4] (IgG1,k) to Human TCF7L2 / TCG4
Immunofluorescence, Western blot, ELISA
Human TCF7L2 / TCG4
Human (tested or 100% immunogen sequence identity)
IgG1,k Monoclonal [3A4]
Protein A purified
Immunofluorescence (10 µg/ml)
IHC - Paraffin
Specificity and Use
TCF7L2 / TCG4 antibody was raised against tCF7L2 (NP_110383, 490 a.a. ~ 597 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Western Blot (Cell lysate) - positive control K-562. Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections, 3 ug/ml) - positive control human colon. Immunofluorescence (10 ug/ml) - positive control HeLa cells. Sandwich ELISA (Recombinant protein).
PBS, pH 7.2
Store at -20°C. Aliquot to avoid freeze/thaw cycles.
Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1.